Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04659096 · ClinicalTrials.gov registry record · Phase 1
A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors
A Phase 1 study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04659096 is a Phase 1 study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT04659096, a Phase 1 study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION537 when administered by intravenous infusion in patients with advanced solid tumors.
Interventions
- DRUG ION537
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2022-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04659096
The ClinicalTrials.gov registry entry for NCT04659096 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ION537 is the first listed.
NCT04659096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04659096 about?
NCT04659096 is a clinical study titled "A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors". The purpose of this study is to evaluate the safety and establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION537 when administered by intravenous infusion in patients with advanced solid tumors.
What is the current status of trial NCT04659096?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-01-05. Estimated completion is 2022-10-19.
What interventions are being tested in trial NCT04659096?
The interventions under investigation include: ION537 (DRUG).
Who is sponsoring clinical trial NCT04659096?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.